Apple tests China’s CXMT memory chips for iPhones and MacBooks, WSJ reports
1 min read
The coverage · 2 reports
- Investing.comFirst reportApple tests China’s CXMT memory chips for iPhones and MacBooks, WSJ reports ↗
- Investing.comLatestApple tests memory chips from China’s CXMT to ease AI-driven supply crunch - WSJ ↗
The story
Apple is testing memory chips made by China’s ChangXin Memory Technologies, or CXMT, for use in iPhones and MacBooks, according to a Wall Street Journal report cited by Investing.com. The report does not provide a qualification decision, order size, launch timing, or expected savings.
The effort touches Apple’s component sourcing across its iPhone and MacBook businesses, which generated FY 2025 revenue of $416.2B, up 6.4% year over year. Apple’s reported gross margin was 46.9% and net margin was 26.9%, so any successful sourcing change would be weighed against product reliability, supply continuity, and component-cost considerations.
The second-order setup is mixed. CXMT testing could broaden Apple’s memory supplier base and improve leverage in procurement, but reliance on a Chinese memory supplier could face export controls, political scrutiny, qualification delays, or product-quality concerns. The next concrete markers are whether CXMT chips pass Apple’s validation process, appear in commercial products, and receive regulatory clearance where required.
The case — both sides
Apple’s $416.2B FY 2025 revenue base and 46.9% gross margin give successful memory diversification potential procurement leverage and supply resilience.
The only concrete development is testing, while unresolved qualification, reliability, export-control, and political risks could prevent any commercial benefit.
The house read
Two-sidedCXMT testing gives AAPL a potential memory-cost and supply-diversification lever, but the immediate read is mixed because qualification, regulatory, and reliability risks remain unresolved.
Wrong ifThe read changes if Apple qualifies CXMT for commercial products with a clearly quantified cost or supply benefit, or if regulatory and reliability concerns halt the effort.
Published read · research, not advice